Longevity Weekly Review 2026-10-28
Week In Review
The metabolic drugs that reshaped obesity medicine have become the yardstick against which the next generation of aging therapies is being measured. At the ARDD 2026 conference in Boston, Eli Lilly reported that tirzepatide lowered epigenetic age estimates by several years in a large trial, while Cambrian Bio’s AMPK activator and David Sinclair’s reprogramming work shared the stage with AI-driven discovery pipelines. The companies now entering the clinic are defining themselves against semaglutide’s known weakness, loss of lean mass: Eos SENOLYTIX is running its mitochondria-targeting geropeptide head to head against semaglutide and retatrutide in aged mice before a planned sarcopenia trial, and Sironax is halfway through enrolling a Phase 2 study of an oral NAD+ booster given alongside semaglutide to see whether it preserves muscle during weight loss.
Beneath the drug programs, the week brought mechanism. A study of primary cilia on hypothalamic neurons ties NAD+ levels, SIRT1, and autophagy together in a single sensory structure that shrinks with age and regrows under caloric restriction, offering a concrete explanation for why those interventions improve metabolic health across the whole body. In the hippocampus, a secreted lipid enzyme called PLA2G2F turns out to be a neuroprotective broadcast signal whose loss causes synapse loss, inflammation, and memory decline in aged mice, and whose restoration prevents them. And a placebo-controlled human study of topical urolithin A showed that activating mitophagy in skin reduces wrinkle depth and inflammatory signaling, a small but real demonstration that cellular quality control can be pharmacologically improved in people.
Many of these claims rest on epigenetic clocks, and the week also delivered a sober reckoning with that instrument. An analysis in Aging Cell, discussed by Fight Aging, proposes three criteria for when a clock result can be trusted and reports that when published single-clock intervention studies are re-run with additional clocks, the extra clocks do not reach significance. XPRIZE Healthspan has chosen a different route, judging its ten finalists on measured muscle, cognitive, and immune function rather than molecular age, while acknowledging the function-based evidence is not yet ready for a regulatory conversation.
The institutional layer is catching up with the science. Lifespan.io’s editor argues that the regulatory bottleneck, not the biology, now limits progress, since therapies that act on shared drivers of aging must still be approved one disease at a time, and points to the FDA’s inclusion of aging in its 2027 regulatory science priorities as a sign of movement. Capital is moving too. Ferring’s agreement to acquire Gameto for up to $1.38 billion puts a major fertility company behind stem-cell-derived ovarian support cells and a menopause program, a signal that ovarian aging is being treated as a distinct and investable segment of aging biology.
Items
ARDD 2026: Tirzepatide Clocks, AMPK Activators, and AI Take the Boston Stage
The Aging Research and Drug Discovery conference, long held in Copenhagen, relocated to Boston this year, and Lifespan.io’s report from the meeting captures a field in which large pharmaceutical companies, academic mechanists, and AI-first drug developers now share the same agenda. The most consequential industry data came from Kevin Duffin of Eli Lilly, who reported that tirzepatide, the company’s dual GLP-1/GIP agonist, reduced biological age estimates by several years in the SURMOUNT-5 trial. According to the report, the improvement showed up across multiple epigenetic clocks and in organ-specific markers of cardiac, immune, renal, and hepatic aging.
The academic talks reached for mechanism. Vishwa Deep Dixit of Yale presented work identifying cysteine and taurine metabolism as checkpoints that regulate the NLRP3 inflammasome, the molecular engine of inflammaging. His team found that calorie-restricted humans shift amino acid metabolism toward taurine production, and that taurine supplementation damped inflammatory responses in aged mice. Vadim Gladyshev of Harvard described heterochronic heart transplantation experiments showing reciprocal aging effects between young and old donor hearts, and released TACO, a free online calculator that estimates transcriptomic age from RNA-sequencing data.
Among the drug developers, James Peyer of Cambrian Bio presented ATX-304, an AMPK activator that produced weight loss comparable to semaglutide in obese mice without the loss of lean mass, along with an 8% increase in resting metabolic rate in Phase 1 human testing. Alex Zhavoronkov of Insilico Medicine showed Phase 2a results for rentosertib, describing a promising trend in lung function and proteomic evidence of three-to-six-year reductions in biological age. David Sinclair reported that OSK reprogramming extended lifespan in progeroid mice by 25 to 33% and showed anti-cancer effects, and described “inflammules,” NAD-consuming structures that accumulate in aging cells.
Two talks pushed back on the computational optimism. Morgan Levine argued that virtual cell models that aim to reproduce raw data are not what aging research needs, calling instead for more general models that capture latent biological states. Derya Unutmaz of the Jackson Laboratory went the other way, advocating AI-powered robotic labs that build probabilistic digital twins for personalized medicine. The FDA’s recent decision to name longevity as a regulatory science priority surfaced repeatedly as the backdrop for all of it.
Source: Lifespan.io
Eos Puts a Mitochondria-Targeting Geropeptide Through Lifespan Studies in Aged Mice
Eos SENOLYTIX is testing a compound called PTC-2105, which it describes as a mitochondrial-targeted geropeptide, in naturally aged mice tracked to natural death. According to Longevity.Technology, the peptide acts on the inner mitochondrial membrane, interacting with cardiolipin and adenine nucleotide translocase proteins to restore membrane potential in healthy cells while pushing senescent cells, which depend on a compromised energy state, toward apoptosis through reduced ATP output. The senolytic effect takes roughly eight weeks to emerge in the animals.
The study design is more ambitious than most preclinical aging work. Survival is the primary endpoint, with locomotor activity measured by a functional composite index, body composition, kidney function via the urinary albumin-to-creatinine ratio, inflammatory markers including IL-6, TNF-alpha, and CXCL10, and spatial memory in a Y-maze. The company is also comparing the peptide directly against semaglutide and retatrutide. Early results reported in the article include improved survival in one cohort with a log-rank p-value of 0.0142, a 70% reduction in urinary albumin at the higher dose, preserved or increased lean mass where semaglutide produced muscle loss, and no rebound weight gain after treatment ended. One animal nicknamed Speedy, aged 167 weeks, outlived its controls by more than 30 weeks.
The article is candid about the limitations. Monitored groups were as small as three to five animals per arm, the Speedy data represent a single mouse over five days, the semaglutide withdrawal comparison came without group sizes or statistics, and the renal protection data showed wide variability despite reaching significance. The company itself rates the cognitive findings as lower confidence than the locomotor and neuromuscular measures. CEO Kevin Slawin framed the goal as ensuring that added years “carry functional vitality,” and the article notes his speculation that cycling on and off semaglutide might accelerate aging, a question no human study has yet been designed to answer.
What comes next is a larger study, SEL-082, with 180 mice comparing continuous and cycled dosing, with results due at the end of 2027, and a planned Phase 1b trial of twelve weeks in people aged 60 and over with sarcopenia. Eos plans to list on Nasdaq through a reverse merger under the ticker MTXL, and works alongside GEROTHERAPEUTIX, the owner of the underlying MitoXcel technology, with sister companies pursuing cancer and consumer applications.
Source: Longevity.Technology
Can an Oral NAD+ Booster Protect Muscle During Semaglutide Weight Loss?
Sironax, a biotech based in Waltham, Massachusetts, reported that its Phase 2 FORGE-LM trial is roughly half enrolled. The study is a double-blind, randomized, placebo-controlled, parallel-group test of SIR4156, which the company describes as a first-in-class oral activator of NAMPT, the rate-limiting enzyme in the pathway that recycles nicotinamide back into NAD+. Participants are adults with obesity, and the compound is given together with semaglutide.
The rationale targets the most discussed drawback of GLP-1 therapy. Semaglutide produces substantial weight loss, but a meaningful share of what is lost is lean muscle rather than fat. According to Longevity.Technology, preclinical work in mouse models showed that SIR4156 produced preferential fat loss, preserved lean mass, reduced muscle atrophy, and improved physical performance. The trial’s primary endpoint is body fat mass and body composition, with body weight, lean mass, safety, tolerability, pharmacokinetics, and pharmacodynamic effects as secondary measures. CEO Shefali Agarwal said that significant unmet needs remain with GLP-1 drugs, “particularly related to lean muscle preservation, fatigue, sustained metabolic health.”
The approach is notable because it reverses the usual direction of NAD+ research. Rather than supplying precursors such as nicotinamide riboside or NMN, which have a long record of modest and inconsistent human results, SIR4156 is a small molecule that increases the activity of the enzyme that makes NAD+ from what the cell already has. If it works, it would be the first pharmacological NAD+ intervention to show a clinically meaningful body-composition effect in a controlled trial.
The company has not disclosed the enrollment target, treatment duration, or a date for results, and the article’s presumed comparison arm of semaglutide plus placebo is not spelled out in the release. SIR4156 is investigational and unapproved, and preclinical body-composition results in mice have a mixed record of translating to people.
Source: Longevity.Technology
How Tiny Antennae on Hypothalamic Neurons Link NAD+, Caloric Restriction, and Whole-Body Aging
Nearly every cell carries a primary cilium, a single hair-like projection that acts as a sensory antenna. On neurons in the hypothalamus, the brain’s master regulator of metabolism, these cilia are critical to how the body senses and responds to nutrient state. A study in Aging Cell, reported by Lifespan.io, shows that hypothalamic cilia shorten with age in parallel with falling NAD+ levels, and that the two are causally connected.
Between 3 and 24 months of age in mice, both cilia length and NAD+ declined in the hypothalamus. In cultured hypothalamic neurons, depleting NAD+ with the drug FK866 significantly shortened cilia, while raising NAD+ with precursors lengthened them. Suppressing CD38, an enzyme that consumes NAD+ and rises with age, proved even more effective than supplying precursors. The sirtuin SIRT1 sits in the middle of the pathway: overexpressing it lengthened cilia, and suppressing it blunted the benefit of added NAD+.
The mechanism involves a protein called CHMP4B, which normally resides in cilia. When NAD+ runs low, CHMP4B relocates to lysosomes, impairing their integrity and the autophagy that depends on them. SIRT1’s deacetylase activity increases the effectiveness of the transcription factor RFX1, which promotes ciliary growth while keeping autophagy pathways intact. The practical test came in 24-month-old mice on caloric restriction, which showed restored cilia length and metabolic measurements comparable to young animals. The authors conclude that hypothalamic primary cilia are required for the metabolic improvements that caloric restriction produces in aged animals.
The finding offers a unifying account of several interventions that have been studied separately. Caloric restriction, NAD+ supplementation, CD38 inhibition, and SIRT1 activation all converge on a single structure in a single brain region that in turn governs systemic metabolism. The work is in mice, and whether human hypothalamic cilia behave the same way remains to be shown, but it points to a direct ciliary target for metabolic disorders of aging.
Source: Lifespan.io
A Secreted Lipid Enzyme Broadcasts Protection to the Aging Hippocampus
The dentate gyrus of the hippocampus is one of the few brain regions that generates new neurons through adulthood, and it is among the first to falter in age-related memory decline. A paper in Nature Neuroscience, discussed by Fight Aging, identifies a secreted phospholipase called PLA2G2F as what the authors describe as a compensatory neuroprotective broadcast signal released by dentate granule cells.
The experiments ran in both directions. Deleting PLA2G2F from dentate granule cells in mice produced a cascade of aging pathology: synapse loss, inflammatory microglia, reactive astrogliosis, impaired neurogenesis, lipid dysregulation, accumulation of lipid droplets, and loss of hippocampus-dependent memory. Boosting PLA2G2F expression during aging prevented those changes and protected memory function. The enzyme’s catalytic activity mobilizes lipid droplets and reduces inflammation, and the neuronal signal it provides decreases the buildup of lipids and cholesterol esters in microglia, the brain’s resident immune cells.
Lipid handling in glia has emerged as a central theme in neurodegeneration research, with lipid-laden microglia implicated in both normal brain aging and Alzheimer’s disease. This work adds a neuron-derived signal that keeps microglial lipid metabolism in check, and shows that the signal is sufficient to prevent the downstream damage when maintained. Because PLA2G2F is secreted, it is in principle the kind of molecule that could be supplemented or whose expression could be induced, making it a candidate therapeutic target for preserving memory and lowering Alzheimer’s risk.
Source: Fight Aging!
Topical Urolithin A Activates Mitophagy and Reduces Wrinkles in a Placebo-Controlled Trial
Urolithin A, a compound produced by gut bacteria from pomegranate ellagitannins, is one of the few mitophagy activators with human clinical data behind it as an oral supplement. A study in iScience, reported by Fight Aging, extends that record to the skin. Researchers tested the molecule in two-dimensional and three-dimensional reconstructed human skin models and in skin explants, then ran randomized, placebo-controlled trials in healthy volunteers.
In the laboratory models, urolithin A enhanced mitochondrial respiration, activated markers of mitophagy, reduced inflammatory mediators and senescence markers, and increased production of extracellular matrix proteins. In the human trials, topical application reduced periorbital wrinkle depth after eight weeks and attenuated the redness produced by UVB exposure. Transcriptomic analysis of treated skin showed increased extracellular matrix and epidermal development programs alongside decreased inflammatory and senescence-associated signaling.
The mechanism is mitophagy, the selective recycling of damaged mitochondria. Aged cells accumulate dysfunctional mitochondria that produce less energy and more oxidative stress, and clearing them restores function. Fight Aging notes that the result complements earlier work on topical rapamycin, another autophagy inducer, and emphasizes that improved autophagy also helps the immune system clear senescent cells, which reduces the inflammatory burden that drives age-related skin dysfunction.
Skin is the most accessible human tissue for testing aging interventions, and it has become a proving ground for mechanisms that are expected to matter everywhere else. A placebo-controlled demonstration that a mitophagy activator changes both the molecular signature and the visible phenotype of aged human tissue is a meaningful step, even if the tissue is one most people think of in cosmetic terms.
Source: Fight Aging!
When Can an Aging Clock Be Trusted? Three Criteria From a New Analysis
Epigenetic clocks, machine-learning models that estimate biological age from DNA methylation patterns, have become the currency in which longevity results are reported. Drugmakers, supplement companies, and academic labs now routinely announce that an intervention lowered biological age by some number of years. A paper in Aging Cell, discussed by Fight Aging, takes a hard look at when such claims deserve credence.
The core problem, as Fight Aging puts it, is that a clock “could underestimate, overestimate, or be unaffected by biological changes that do have meaningful effects on aging.” A clock is trained on correlations between methylation and age or mortality in untreated populations, and there is no guarantee that an intervention which alters methylation at the clock’s sites is doing anything to the underlying biology, or that an intervention which helps the biology will move those particular sites. For a novel treatment, the clock has never been validated against the outcome that matters.
The authors propose three criteria that together raise confidence. First, reliable principal-component-based clocks, which are less noisy than single-site clocks, should respond. Second, clocks trained on mortality or pace of aging, rather than on chronological age alone, should respond. Third, multiple clocks should move in the same direction. The paper’s most pointed finding is empirical: when previously published single-clock intervention studies were extended to include additional clock models, no additional clocks reached statistical significance. That suggests a number of reported age reversals may be artifacts of clock selection.
The timing is apt. The week’s conference reports included multi-year clock reductions attributed to tirzepatide and rentosertib, and skin-age reductions from topical drugs have made headlines this month. The criteria offer readers a simple filter: a result that moves one clock is a hypothesis, while a result that moves several independent, mortality-trained clocks in concert is evidence.
Source: Fight Aging!
The Regulatory Bottleneck in Aging Biology
Steve Hill, editor in chief of Lifespan.io, argues that the pace of progress in aging medicine is now set less by what the biology allows than by how regulators are organized to evaluate it. Current frameworks treat age-related diseases as isolated conditions, each requiring its own approval, even though the hallmarks-of-aging research program has spent a decade showing that they share upstream drivers. A therapy that repairs a common mechanism must therefore assemble what Hill describes as largely separate clinical packages, repeated safety work, and new endpoint negotiations for every indication it expands into.
The piece grounds the economic stakes in two recent institutional reports, a 2025 International Monetary Fund analysis and a 2026 World Economic Forum report on the longevity dividend, both of which find large fiscal benefits from extending healthspan. It also treats the FDA’s inclusion of aging and longevity in its 2027 Focus Areas of Regulatory Science as a formal acknowledgment that the current structure is a problem, and notes ARPA-H’s PROSPR biomarker program and the Alliance for Longevity Initiatives’ proposed Multi-Disease Therapeutic Designation, put forward for the next PDUFA reauthorization, as live efforts to address it.
Hill’s proposals are specific. Platform technology designations would let core safety data carry across indications. Multi-disease or hallmark-based pathways would recognize shared biology. Validated surrogate endpoints, including epigenetic clocks and composite functional measures, would shorten trials. Adaptive approval models would allow iterative improvement without restarting review, and international convergence among the FDA, the UK’s MHRA, the EMA, Japan’s regulator, Health Canada, Australia’s TGA, and Singapore’s HSA would prevent the data from being re-litigated in every jurisdiction. He cites Japan’s conditional approval pathway for regenerative products, with its seven-year limit, as a working example.
The argument anticipates its main objection, that regulatory conservatism exists to protect patients, by contending that modernization preserves rigorous safety standards while removing structural delay that no longer serves a protective purpose. The risk Hill flags is fragmentation: if jurisdictions move at different speeds, the result will be regulatory arbitrage and unequal access rather than faster medicine.
Source: Lifespan.io
XPRIZE Healthspan: The $101 Million Question Isn’t Who Wins
XPRIZE Healthspan has narrowed a field of roughly 800 early registrants to ten finalists, each receiving $1 million in unrestricted capital plus shared trial infrastructure that Longevity.Technology values at $2 million to $2.5 million per team. Kyle Umipig’s piece, built around interviews with Jamie Justice, the foundation’s health domain director, and Steven Cummings, the UCSF professor emeritus who chairs the judging panel, argues that the competition’s real product is not a winner but a measurement methodology the field has lacked.
Justice draws the distinction between a prize and a grant sharply: “A prize actually pays for proof and demonstration, and it sticks to a very tight timeline.” Grants fund effort; a prize funds a result, delivered by a date, against a pre-specified standard. The standard here is functional rather than molecular. Finalists must demonstrate improvement in three domains in people: muscle function, assessed by six-minute walk tests; cognition, assessed by computer-based task switching; and immune function. The choice of endpoints is deliberate. Function is what patients and payers care about, and it sidesteps the question of whether any given molecular clock is measuring something real.
The article does not oversell the design. Justice concedes a central limitation: asked whether the evidence exists for a regulatory conversation based on function right now, her answer is no. One-year trials cannot predict decades of aging, powerful mechanisms carry safety concerns, recruitment difficulties could sink promising candidates, and individual variation may mean no single intervention works for everyone. The value, in this telling, is that ten teams will generate comparable functional data on the same timeline using shared infrastructure, which is closer to a standardized evidence base than the field has had.
Read alongside the week’s debate over epigenetic clocks, the prize represents the other horn of the measurement dilemma. Clocks are fast and cheap but of uncertain meaning; functional endpoints are meaningful but slow and expensive. XPRIZE is betting that the second kind of evidence, generated in parallel across ten mechanisms, will be what eventually moves regulators.
Source: Longevity.Technology
Ferring Moves to Acquire Gameto in a Deal Worth Up to $1.38 Billion
Ferring, the Swiss pharmaceutical company with more than fifty years in fertility medicine and distribution across more than a hundred countries, has agreed to acquire the US biotech Gameto in a transaction valued at up to $1.3825 billion, according to Longevity.Technology. The total includes development, regulatory, and commercial milestones whose specific terms were not disclosed, and the deal awaits customary closing conditions.
Gameto builds therapies from induced pluripotent stem cells for reproductive health. Its lead program, Fertilo, uses engineered ovarian support cells to mature eggs outside the body, which reduces the duration of hormone injections and the burden of ovarian stimulation compared with conventional IVF. The company reports that Fertilo has facilitated multiple healthy births in countries where it holds regulatory approval, though it remains investigational in the United States and has not been approved by the FDA. A second program, Ameno, applies the same cell platform to menopause.
The strategic logic runs in both directions. Ferring gains a cell-engineering platform to add to a conventional fertility portfolio, and Gameto gains the funding and regulatory experience needed to carry Fertilo through US approval. Ferring CEO Jean-Frédéric Paulsen described the combination as “an opportunity to advance new approaches in fertility care.” For the longevity field, the deal is a marker: a major pharmaceutical company is paying a billion-dollar price for a company whose scientific premise is that the ovary ages on its own accelerated schedule and that this aging can be engineered around.
The article is careful about what has not yet been shown. Fertilo’s route into fertility clinics depends on regulatory approval and on demonstrating safety and pregnancy success rates in controlled studies, and the menopause program could require decades to prove efficacy. Whether progress on ovarian biology will translate to broader female aging remains an open question. But the ovary is the first human organ to fail from aging, typically decades before the rest of the body, and it has long been proposed as the natural first target for interventions meant eventually to reach everything else.
Source: Longevity.Technology